SCHEMBL21899747

SCHEMBL21899747

C=N/C=N\N=N/C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523958 0.65
SCHEMBL12952131 0.65
SCHEMBL903201 0.63
SCHEMBL15006086 0.62
SCHEMBL20960442 0.61
SCHEMBL19234944 0.57
SCHEMBL16152242 0.57
SCHEMBL15580548 0.56
SCHEMBL16449139 0.56
SCHEMBL15039574 0.53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240213475-A1 ADDITIVE FOR ELECTROLYTE, ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY, AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME SAMSUNG SDI CO., LTD. (KR) 2024-06-27 US disclosed
WO-2023235384-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2023-12-07 WO disclosed
WO-2023214552-A1 TRIFLUOROMETHANE SULFONYLATION AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANE SULFONYL COMPOUND セントラル硝子株式会社 2023-11-09 WO disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
US-11588208-B2 Lithium ion battery using crosslinkable separator ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-02-21 US disclosed
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-01-26 US disclosed
US-20230025892-A1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2023-01-26 US disclosed
WO-2022133480-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-06-23 WO disclosed
EP-3409674-B1 PROCESS FOR PREPARING COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORP (US) 2022-04-06 EP disclosed
US-11285101-B2 Soft chewable pharmaceutical products INTERVET INC. (US) 2022-03-29 US disclosed
EP-3564235-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) Northwestern University (US) 2019-11-06 EP disclosed
US-20190210978-A1 HIV PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2019-07-11 US disclosed
US-20190201332-A1 Soft Chewable Pharmaceutical Products INTERVET INC. (US) 2019-07-04 US disclosed
US-20190169209-A1 NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2019-06-06 US disclosed
US-20190151330-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2019-05-23 US disclosed
EP-2961435-B1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN INC (US) 2019-05-01 EP disclosed
WO-2019057196-A1 FLUORESCENT COMPOUNDS FOR LIPID DROPLET IMAGING AND IMAGE-GUIDED PHOTODYNAMIC THERAPY THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2019-03-28 WO disclosed
US-10189830-B2 Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders BIOELECTRON TECHNOLOGY CORPORATION (US) 2019-01-29 US disclosed
EP-3424905-A1 HETEROCYCLIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2019-01-09 EP disclosed
EP-3252041-A1 BIPYRIDINE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL Sumitomo Chemical Company, Limited (JP) 2017-12-06 EP disclosed